<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01282762</url>
  </required_header>
  <id_info>
    <org_study_id>DV2-HBV-19</org_study_id>
    <nct_id>NCT01282762</nct_id>
  </id_info>
  <brief_title>Long-Term Study on Safety and Immunogenicity of HEPLISAV™ and Engerix-B® in Adults With Chronic Kidney Disease</brief_title>
  <official_title>An Observational Study Evaluating the Long-Term Safety and Immunogenicity of HEPLISAV™ Compared With Engerix-B® in Adults With Chronic Kidney Disease Who Have Previously Received At Least One Hepatitis B Vaccine Series</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dynavax Technologies Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dynavax Technologies Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the durability of seroprotection of HEPLISAV™ and
      Engerix-B® and the number of injections of each vaccine needed to maintain seroprotection in
      a cohort of chronic kidney disease (CKD) patients over time.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An Observational Study Evaluating the Long-Term Safety and Immunogenicity of HEPLISAV™
      compared with Engerix-B® in Adults with Chronic Kidney Disease who Have Previously Received
      At Least One Hepatitis B Vaccine Series
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the durability of seroprotection induced by HEPLISAV and Engerix-B as measured by seroprotection rate (SPR) (anti-HBsAg&gt; 10 milli-international unit (mIU)/mL</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the durability of seroprotection induced by HEPLISAV and Engerix-B as measured by SPR (anti-HBsAg&gt; 10 mIU/mL</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the durability of seroprotection induced by HEPLISAV and Engerix-B as measured by SPR (anti-HBsAg&gt; 10 mIU/mL</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the durability of seroprotection induced by HEPLISAV and Engerix-B as measured by SPR (anti-HBsAg&gt; 10 mIU/mL</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the durability of seroprotection induced by HEPLISAV and Engerix-B as measured by SPR (anti-HBsAg&gt; 10 mIU/mL</measure>
    <time_frame>36 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the durability of seroprotection induced by HEPLISAV and Engerix-B as measured by SPR (anti-HBsAg&gt; 10 mIU/mL</measure>
    <time_frame>48 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety of HEPLISAV and Engerix-B in CKD subjects who previously received at least one hepatitis B vaccine series.</measure>
    <time_frame>Baseline and 6,12, 24, 36 and 48 months</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">147</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HEPLISAV</intervention_name>
    <description>0.5 mL administered intramuscularly (IM) at Week 0, Week 4 and Week 24.
HEPLISAV booster injection = one dose of 0.5 mL volume when needed.</description>
    <other_name>Hepatitis B vaccine (recombinant), adjuvanted</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Engerix-B</intervention_name>
    <description>2.0 mL administered intramuscularly (IM) at Week 0, Week 4, Week 8 and Week 24.
Engerix-B booster injection = one dose of 2.0 mL volume when needed</description>
    <other_name>Hepatitis B vaccine (recombinant)</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum retained during study duration for additional testing if indicated
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects with Chronic Kidney Disease previously enrolled in the Dynavax clinical studies
        DV2-HBV-17 and DV2-HBV-18
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        A subject must meet all of the following inclusion criteria to participate in the study:

          -  enrolled and completed HEPLISAV or Engerix-B treatment in: DV2-HBV-17 or DV2-HBV-18
             and had anti-HBsAg ≥ 10 mIU/mL prior to or during DV2-HBV-18

          -  previously received a complete primary hepatitis B vaccine series in DV2-HBV-17 or
             prior to enrollment in DV2-HBV-18

          -  be otherwise clinically stable in the opinion of the investigator

          -  be able and willing to provide informed consent

        Exclusion Criteria:

        A subject who meets any ONE of the following exclusion criteria is not permitted to
        participate in the study:

          -  previously enrolled in DV2-HBV-18 and never obtained anti-HBsAg ≥ 10 mIU/mL

          -  received hepatitis B vaccine off-study after enrolling in DV2-HBV-17 or DV2-HBV-18

          -  has known history of autoimmune disease

          -  is unwilling or unable to comply with all the requirements of the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Research Associates of Tidewater</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.Dynavax.com</url>
  </link>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 20, 2011</study_first_submitted>
  <study_first_submitted_qc>January 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2011</study_first_posted>
  <last_update_submitted>February 27, 2018</last_update_submitted>
  <last_update_submitted_qc>February 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prevention of Hepatitis B infection.</keyword>
  <keyword>End Stage Renal Disease</keyword>
  <keyword>Hepatitis B vaccination</keyword>
  <keyword>Hepatitis B virus (HBV)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>No Changes to status a/o 3/2017</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

